Showing results (111-120 of 122) with videos related to

Sort By:
Pageof 13
The Journal of Antimicrobial Chemotherapy|February 19, 2008
Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patientsChristoph Wyen, Heidy Hendra, Martin Vogel, et al.
HIV Research & Clinical Practice|March 2, 2022
Switching to a NRTI-free 2 drug regimen (2DR) -a sub-analysis of the 48 weeks DUALIS study on metabolic and renal changesMalte Monin, Tim Kümmerle, Jochen Schneider, et al.
The Journal of Antimicrobial Chemotherapy|July 1, 2011
Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimensChristoph Wyen, Heidy Hendra, Marco Siccardi, et al.
AIDS Care|April 26, 2021
Health-related quality-of-life in people living with HIV after switching to dual therapy with ritonavir-boosted darunavir + dolutegravir: a DUALIS sub-studyElisabeth Olliges, Bernhard Bührlen, Franz Fischer, et al.
Open Forum Infectious Diseases|September 23, 2020
Efficacy and Safety of Switching to Dolutegravir With Boosted Darunavir in Virologically Suppressed Adults With HIV-1: A Randomized, Open-Label, Multicenter, Phase 3, Noninferiority Trial: The DUALIS StudyChristoph D Spinner, Tim Kümmerle, Jochen Schneider, et al.
The Lancet. HIV|October 14, 2021
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority studyHans Jaeger, Edgar T Overton, Gary Richmond, et al.
Open Forum Infectious Diseases|September 24, 2021
Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 StudyGraham H R Smith, W Keith Henry, Daniel Podzamczer, et al.
Journal of Circadian Rhythms|April 15, 2024
Timely Questions Emerging in Chronobiology: The Circadian Clock Keeps on TickingSangeeta Chawla, John O'Neill, Marina I Knight, et al.
Lancet (London, England)|December 14, 2020
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority studyEdgar T Overton, Gary Richmond, Giuliano Rizzardini, et al.
Frontiers in Immunology|August 1, 2022
Host KIR/HLA-C Genotypes Determine HIV-Mediated Changes of the NK Cell Repertoire and Are Associated With Vpu Sequence Variations Impacting Downmodulation of HLA-CSarah Vollmers, Annabelle Lobermeyer, Annika Niehrs, et al.
Pageof 13